10x Genomics (NASDAQ:TXG) Posts Quarterly Earnings Results

10x Genomics (NASDAQ:TXG) issued its earnings results on Thursday. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.19, FiscalAI reports. The company had revenue of $150.84 million for the quarter, compared to analyst estimates of $146.41 million. 10x Genomics had a negative net margin of 6.77% and a negative return on equity of 6.89%. The business’s revenue was up 9.4% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.28) EPS.

Here are the key takeaways from 10x Genomics’ conference call:

• Atera launch is the company’s largest product introduction, enabling spatial whole-transcriptome with single-cell sensitivity at scale and generating “extraordinary” early customer interest and pre-orders ahead of initial H2 2026 shipments.
• Consumables and margins showed strength in Q1 — revenue was $150.8M (up ~9% YoY excluding a one-time settlement), total consumables +13% (spatial consumables +31%), gross margin 70%, and cash balance of $540M (+$113M YoY).
• Instrument revenue declined materially (total instruments -24%, spatial instruments -32%), and management expects a Q2 sequential step-down as some customers delay purchases waiting for Atera; Atera production capacity will be limited in 2026 with roughly ~40 units expected between Q3–Q4.
• Company is positioning for a structural AI and translational tailwind — multiple partnerships and initiatives (e.g., Chan Zuckerberg, Bioptimus) aim to scale biological data generation, expanding the long-term TAM but with uncertain near-term revenue timing.

10x Genomics Stock Performance

TXG stock traded down $0.82 during trading on Friday, hitting $21.60. The stock had a trading volume of 4,830,148 shares, compared to its average volume of 2,612,894. The company’s 50 day moving average price is $21.53 and its two-hundred day moving average price is $18.96. 10x Genomics has a 1-year low of $8.06 and a 1-year high of $26.44. The stock has a market cap of $2.76 billion, a price-to-earnings ratio of -61.71 and a beta of 2.05.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. TD Cowen lifted their price target on 10x Genomics from $18.00 to $19.00 and gave the stock a “hold” rating in a research note on Friday, February 13th. Bank of America lifted their price target on 10x Genomics from $21.00 to $30.00 and gave the stock a “neutral” rating in a research note on Monday, April 20th. Leerink Partners cut their price target on 10x Genomics from $22.00 to $20.00 and set a “market perform” rating for the company in a research note on Tuesday, January 27th. William Blair raised shares of 10x Genomics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 31st. Finally, Zacks Research raised shares of 10x Genomics from a “hold” rating to a “strong-buy” rating in a research note on Friday, April 17th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, 10x Genomics currently has a consensus rating of “Hold” and a consensus target price of $20.82.

Key Stories Impacting 10x Genomics

Here are the key news stories impacting 10x Genomics this week:

• Positive Sentiment: 10x Genomics reported Q1 revenue of $150.8 million and EPS of -$0.10, both better than Wall Street expectations, with revenue up 9.4% year over year and gross margin improving. Article: 10x Genomics Q1 Earnings & Revenues Beat Estimates, Gross Margin Up
• Positive Sentiment: William Blair reiterated a Buy rating, citing strong Q1 results, an improved growth outlook tied to Atera, and attractive valuation. Article: 10x Genomics: Buy Rating Reaffirmed on Strong Q1, Atera-Driven Growth Outlook, and Attractive Valuation
• Neutral Sentiment: The company’s earnings call transcript and earnings coverage are drawing attention as investors look for more detail on management’s plans and the sustainability of margin improvement. Article: 10x Genomics, Inc. (TXG) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Despite the beat, 10x Genomics still posted a loss and remains unprofitable, and the company’s FY2026 revenue outlook of $600 million to $625 million is only modestly above consensus. Article: 10x Genomics Reports First Quarter 2026 Financial Results

Insider Activity at 10x Genomics

In related news, insider Benjamin J. Hindson sold 7,826 shares of the business’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $18.58, for a total value of $145,407.08. Following the completion of the transaction, the insider owned 424,779 shares of the company’s stock, valued at approximately $7,892,393.82. The trade was a 1.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Serge Saxonov sold 10,000 shares of the business’s stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $19.13, for a total transaction of $191,300.00. Following the completion of the transaction, the chief executive officer directly owned 1,177,273 shares of the company’s stock, valued at $22,521,232.49. The trade was a 0.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 46,426 shares of company stock valued at $902,695. 8.84% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Van ECK Associates Corp increased its stake in shares of 10x Genomics by 85.9% during the 4th quarter. Van ECK Associates Corp now owns 3,668 shares of the company’s stock valued at $60,000 after acquiring an additional 1,695 shares during the last quarter. EverSource Wealth Advisors LLC increased its stake in shares of 10x Genomics by 203.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 7,490 shares of the company’s stock valued at $87,000 after acquiring an additional 5,025 shares during the last quarter. Focus Partners Wealth acquired a new position in shares of 10x Genomics during the 1st quarter valued at about $92,000. CIBC Bancorp USA Inc. acquired a new position in shares of 10x Genomics during the 3rd quarter valued at about $134,000. Finally, EP Wealth Advisors LLC acquired a new position in shares of 10x Genomics during the 4th quarter valued at about $188,000. Institutional investors and hedge funds own 84.68% of the company’s stock.

About 10x Genomics

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.